Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications

Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)

(2017) D. J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

(2010) Jose J. Mansure et al.   CANCER BIOLOGY & THERAPY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

(2009) Simon J. Dovedi et al.   CANCER AND METASTASIS REVIEWS

Targeting Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

EFFECTS OF MTOR INHIBITOR EVEROLIMUS (RAD001) ON BLADDER CANCER CELLS

(2009) Edmund Chiong et al.   JOURNAL OF UROLOGY

QUANTIFICATION OF SUNITINIB'S ANTITUMOR EFFECTS IN A LOCALIZED ORTHOTOPIC BLADDER CANCER MODEL

(2009) Amit R Patel et al.   JOURNAL OF UROLOGY

Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting

(2008) David J. Gallagher et al.   CANCER

Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry

(2008) Ferenc Pinter et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

(2008) Guru Sonpavde et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Rapamycin Inhibits In Vitro Growth and Release of Angiogenetic Factors in Human Bladder Cancer

(2008) Guido Fechner et al.   UROLOGY

Molecular targets and targeted therapies in bladder cancer management

(2008) Ramy F. Youssef et al.   WORLD JOURNAL OF UROLOGY

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE

Hypoxia-inducible factor-1  expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma

(2007) C-Y Chai et al.   JOURNAL OF CLINICAL PATHOLOGY